By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Genentech, Inc. et al. v. Glaxo Group Ltd. et al.
2:11-cv-03065; filed April 12, 2011 in the Central District of California
• Plaintiffs: Genentech, Inc.; City of Hope
• Defendants: Glaxo Group Ltd.; GlaxoSmithKline LLC; Human Genome Sciences, Inc.; Lonza Biologics PLC; Lonza Biologics Inc.
Infringement of U.S. Patent No. 7,923,221 ("Methods of Making Antibody Heavy and Light Chains Having Specificity for a Desired Antigen," issued April 12, 2011) based on defendants' manufacture and sale of their Benlysta® (belimumab, under development for the treatment of seropositive patients with systemic lupus erythematosus) and Arzerra (ofatumumab, used to treat chronic lymphocytic leukemia) products. View the complaint here.
Nautilus Neurosciences, Inc. et al. v. Wockhardt USA LLC et al.
2:11-cv-01997; filed April 8, 2011 in the District Court of New Jersey
• Plaintiffs: Nautilus Neurosciences, Inc.; APR Applied Pharma Research SA
• Defendants: Wockhardt USA LLC; Wockhardt Ltd.
Infringement of U.S. Patent Nos. 6,974,595 ("Pharmaceutical Compositions Based on Diclofenac," issued December 13, 2005), 7,482,377 ("Pharmaceutical Compositions and Methods of Treatment Based on Diclofenac," issued January 27, 2009), and 7,759,394 ("Diclofenac Formulations and Methods of Use," issued July 10, 2010) following a Paragraph IV certification as part of Wockhardt's filing of an ANDA to manufacture a generic version of Nautilus' Cambia® (diclofenac potassium, used for the acute treatment of migraine attacks). View the complaint here.
Purdue Pharma L.P. et al. v. Ranbaxy Inc. et al.
1:11-cv-02401; filed April 8, 2011 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies
• Defendants: Ranbaxy Inc.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Laboratories Ltd.
Infringement of U.S. Patent Nos. 7,674,799 ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title, issued March 9, 2010), and 7,683,072 (same title, issued March 23, 2010) following a Paragraph IV certification as part of Raxbaxy's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Purdue Pharma L.P. et al. v. Impax Laboratories, Inc.
1:11-cv-02400; filed April 8, 2011 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies; Board of Regents of the University Of Texas Systems; Grunenthal GmbH
• Defendants: Impax Laboratories, Inc.
Infringement of U.S. Patent Nos. 6,488,963 ("Hot-Melt Extrudable Pharmaceutical Formulation," issued December 3, 2002), 7,674,799 ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title, issued March 9, 2010), 7,683,072 (same title, issued March 23, 2010), and 7,776,314 ("Abuse-Proofed Dosage System," issued August 17, 2010) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Takeda Pharmaceutical Co., Ltd. et al. v. Impax Laboratories, Inc.
3:11-cv-01610; filed April 1, 2011 in the Northern District of California
• Plaintiffs: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceuticals LLC; Takeda Pharmaceuticals America, Inc.
• Defendant: Impax Laboratories, Inc.
Infringement of U.S. Patent Nos. 6,462,058 ("Benzimidazole Compound Crystal," issued October 8, 2002), 6,664,276 (same title, issued December 16, 2003), 6,939,971 (same title, issued September 6, 2005), 7,285,668 ("Process for the Crystallization of (R)- or (S)-Lansoprazole," issued October 23, 2007), and 7,790,755 ("Controlled Release Preparation," issued September 7, 2010) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease). View the complaint here.
Celgene Corp. et al. v. Mylan Pharmaceuticals Inc.
2:11-cv-01882; filed April 1, 2011 in the District Court of New Jersey
• Plaintiffs: Celgene Corp.; Novartis Pharmaceuticals Corp.; Novartis Pharma AG
• Defendant: Mylan Pharmaceuticals Inc.
Infringement of U.S. Patent Nos. 5,908,850 ("Method of Treating Attention Deficit Disorders with d-Threo Methylphenidate," issued June 1, 1999), 6,355,656 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 12, 2002, with a reexamination certificate issued March 27, 2007), 6,528,530 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 4, 2003), 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998), 6,635,284 (same title, issued October 21, 2003), and 7,431,944 ("Delivery of Multiple Doses of Medications," issued October 7, 2008) all licensed exclusively to Novartis in certain fields of use, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Focalin XR® (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Comments